ArticlePatient preference and adherence2018
Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling.
Article in Patient preference and adherence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Factors Influencing Physician Adherence to Venous Thromboembolism Risk Assessment Model Recommendations: A Best-Worst Scaling.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Article
- Treatment Goals in Schizophrenia: Subgroup Analysis of a Survey in Matched Physician-Patient Pairs.Patient preference and adherence · 2025Article
- Quantifying the Tolerability of Antipsychotic Treatment-Related Side Effects in Schizophrenia: A Survey Study of Patients and Caregiver Proxies.Patient preference and adherence · 2025Article
- Identification and Rating of Treatment Goals in Schizophrenia: Delphi Process and Concordance Survey in Matched Physician-Patient Pairs.Patient preference and adherence · 2025Article
- Lost and found: dynamics of relationship and employment status over time in people with affective and psychotic spectrum disorders.BJPsych open · 2024Article
- Preferences of Young Adults With Psychosis for Cannabis-Focused Harm Reduction Interventions: A Cross-Sectional Study: Préférences des jeunes adultes souffrant de psychose pour les interventions de réduction des méfaits axées sur le cannabis : une étude transversale.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Article
- Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study.Journal of managed care & specialty pharmacy · 2024Observational
- Hospitalization and help-seeking among first episode psychosis patients.Discover mental health · 2024Article
- Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives.Journal of general internal medicine · 2023Article
- Factors Influencing Patient and Caregiver Preferences for Antipsychotic Treatment of Schizophrenia in China: A Discrete Choice Experiment.Patient preference and adherence · 2023Article
- Prioritizing Treatment Goals of People Diagnosed with Bipolar I Disorder in the US: Best-Worst Scaling Results.Patient preference and adherence · 2023Article
- Understanding the Treatment Preferences of People Living with Schizophrenia in Australia; A Patient Value Mapping Study.Patient preference and adherence · 2022Article
- Article
- Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.European psychiatry : the journal of the Association of European Psychiatrists · 2021Observational
- Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection.Neuropsychiatric disease and treatment · 2021Article
- Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study.Clinical drug investigation · 2020Article
- Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia.Neuropsychiatric disease and treatment · 2020Article
- Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey.Patient preference and adherence · 2020Article
- Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.Patient preference and adherence · 2020Article
- Prioritizing outcome preferences in patients with ocular hypertension and open-angle glaucoma using best-worst scaling.Ophthalmology. GlaucomaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan.
methodsPeople aged 18-35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best-worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment.
resultsAcross 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%;
conclusionsPeople with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.